Of all the controversial plays on Wall Street, penny stocks take the cake. The risk-tolerant flock to these names as the potential for …
Roth Capital analysts are weighing in on solar-system company SolarCity Corp (NASDAQ:SCTY) and biotech company ContraFect Corp (NASDAQ:CFRX), as news of a potential investment tax credit extension and Phase 1 …
In a research report issued yesterday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on ContraFect Corp. (NASDAQ:CFRX) with a price target …
In a research report issued today, Roth Capital analyst Joseph Pantginis initiated coverage on ContraFect Corporation (CFRX) with a Buy rating and a $14 price target, which represents …
